{'52WeekChange': -0.6221945,
 'SandP52WeekChange': None,
 'address1': '950 Winter Street',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 3.23,
 'askSize': 900,
 'averageDailyVolume10Day': 214900,
 'averageVolume': 147855,
 'averageVolume10days': 214900,
 'beta': 2.669562,
 'beta3Year': None,
 'bid': 2.94,
 'bidSize': 1000,
 'bookValue': 0.654,
 'category': None,
 'circulatingSupply': None,
 'city': 'Waltham',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 3.02,
 'dayLow': 2.92,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -1.918,
 'enterpriseToRevenue': None,
 'enterpriseValue': 92609400,
 'exDividendDate': None,
 'exchange': 'NGM',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 3.0785713,
 'fiftyTwoWeekHigh': 9,
 'fiftyTwoWeekLow': 1.44,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 25141305,
 'forwardEps': -0.83,
 'forwardPE': -3.5421689,
 'fromCurrency': None,
 'fullTimeEmployees': 29,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'headSymbol': None,
 'heldPercentInsiders': 0.111770004,
 'heldPercentInstitutions': 0.53694,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': 1513728000,
 'lastSplitFactor': '1:20',
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/eloxxpharma.com',
 'longBusinessSummary': 'Eloxx Pharmaceuticals, Inc., a clinical-stage '
                        'biopharmaceutical company, develops novel ribonucleic '
                        'acid for the treatment of rare and ultra-rare '
                        'premature stop codon diseases. Its lead program is '
                        'ELX-02, which has completed Phase 1 clinical trial '
                        'that focuses on the treatment of cystic fibrosis and '
                        'cystinosis patients with diagnosed nonsense '
                        'mutations. The company was founded in 2013 and is '
                        'headquartered in Waltham, Massachusetts.',
 'longName': 'Eloxx Pharmaceuticals, Inc.',
 'market': 'us_market',
 'marketCap': 117976032,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_251924233',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -52903000,
 'nextFiscalYearEnd': 1640908800,
 'open': 3.02,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '781-577-5300',
 'previousClose': 3.03,
 'priceHint': 4,
 'priceToBook': 4.495413,
 'priceToSalesTrailing12Months': None,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 3.02,
 'regularMarketDayLow': 2.92,
 'regularMarketOpen': 3.02,
 'regularMarketPreviousClose': 3.03,
 'regularMarketPrice': 3.02,
 'regularMarketVolume': 27744,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 40127900,
 'sharesPercentSharesOut': 0.032899998,
 'sharesShort': 1319797,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 472523,
 'shortName': 'Eloxx Pharmaceuticals, Inc.',
 'shortPercentOfFloat': 0.0467,
 'shortRatio': 7.08,
 'startDate': None,
 'state': 'MA',
 'strikePrice': None,
 'symbol': 'ELOX',
 'threeYearAverageReturn': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -1.353,
 'twoHundredDayAverage': 3.296331,
 'underlyingExchangeSymbol': None,
 'underlyingSymbol': None,
 'uuid': '7757fdb9-f155-34f0-bdd9-831d75d189da',
 'volume': 27744,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.eloxxpharma.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '02451'}